CEO and President of Premier Biomedical, Inc., William A. Hartman, talked with Stock Day’s Everett Jolly about recent issues facing his industry and company.
PHOENIX, Oct. 02, 2018 (GLOBE NEWSWIRE) -- Premier Biomedical, Inc. (OTCQB:BIEI) (“Premier Biomedical, Inc.” or the “company”) is looking for new strategies and joint ventures to sell CBD. CEO and President of Premier Biomedical, Inc., William A. Hartman, talked with Stock Day’s Everett Jolly about recent issues facing his industry and company.
Mr. Jolly asked Mr. Hartman where Premier Biomedical, Inc. stands on a recent joint venture. He eluded to a few issues that have arisen but says their reasons for wanting to pursue a joint venture are as relevant as ever.
“We are targeting Europe,” explained Mr. Hartman. “In Europe, CBD was declared a medicine. In order to enter the market, we have to make a joint venture in Europe.”
He then went on to explain that they selected a partner and were poised to move forward. In the meantime, the company they hoped to work alongside was targeted for takeover by a third company and that has slowed the joint venture down.
“In the interim, we have picked another company with whom to have a joint venture. This company is not quite as desirable, but because of laws in different countries involved with these partners we can actually have two joint ventures.”
Mr. Hartman then told Mr. Jolly that while Premier Biomedical, Inc. was exploring these joint ventures a mass distributor, with 15,000 outlets in the U.S., decided to start handling CBD and chose Premier Biomedical, Inc.
“This mass distributor has noted we need entry level products,” said Hartman. “Just this week we’ve identified 5 new products and we are working on pricing.”
Mr .Hartman also acknowledged to Mr. Jolly that his industry needs to do more on social media and other public forums to make sure people realize that CBD is a pain relief drug and is a legal drug.
“Hartman stated that Premier has continued to present their products to the DOD and is confident that the Hemp Farming Act of 2018, S-2667, sponsored by Senators Rand Paul and Mitch McConnell, will be the catalyst that opens up sales opportunities with the DOD as well as with social media.”
Hartman also added that he is confident in a bright future for topical hemp oil/ CBD pain relief products and for Premier Biomedical as a leader in that market.
To hear more about Premier Biomedical, Inc. challenges and future outlook listen to the entire Stock Day podcast here: https://upticknewswire.com/featured-interview-ceo-william-hartman-of-premier-biomedical-inc-otcqb-biei-10/
About Premier Biomedical, Inc.
Premier Biomedical, Inc. has acquired exclusive licenses for patent-pending medications/medical procedures to develop cures for a significant number of the most debilitating and often fatal illnesses affecting mankind: Amyotrophic Lateral Sclerosis (ALS), Traumatic Brain Injury (TBI), Multiple Sclerosis (MS), Clinical Depression, Alzheimer’s Disease, Blood Sepsis, Atherosclerosis, and Cancer. We have developed an aggressive timetable to advance the development of these breakthrough technologies through laboratory, hospital, and clinical trials. We have initiated the development of potential patient trial application lists. We have a management team with extensive experience and contacts in the medical/pharmaceutical fields as well as a demonstrated track record of launching new business ventures in a competitive environment. Our extensive contacts in the medical/pharmaceutical industries will ensure that new developments will achieve maximum visibility and exposure to the market. Transparency and accountability will continue to be ensured via regular issuance of technical progress reports, financials, and investor relations reports to maintain investor enthusiasm.
For more information: http://www.premierbiomedical.com/
About William Hartman
William A. Hartman, is our President and Chief Executive Officer and a member of our Board of Directors. From March 2008 until June 2010, Mr. Hartman was planning the formation of Premier Biomedical, Inc. From October 2006 to March 2008, Mr. Hartman was the Chief Operating Officer of Nanologix, Inc. From July 1991 to July 2000, Mr. Hartman was a Director at TRW Automotive. From 1984 to 1991, Mr. Hartman was Chief Engineer at TRW Automotive and from 1979 to 1984, he was Division Quality Compliance Manager at Ford Motor Company. At TRW Automotive, Mr. Hartman was one of the auto industry pioneers of the concept of grouping related components into systems and modules and shipping just-in-time to the vehicle assembly plants. He founded and headed a separate business group within TRW Automotive with plants in the U.S., Mexico and Europe with combined annual sales of $1.3 Billion. Academic credentials include a BSME degree from Youngstown State University and a MSIA degree (Industrial Administration/Management) from the University of Michigan.
Contact:
William A. Hartman
PO Box 25
Jackson Center, PA 16133
Phone: (724) 633-7033
W.Hartman@PremierBiomedical.com
Premier Biomedical, Inc., a Nevada corporation, is a fully reporting issuer under the Securities Exchange Act of 1934, listed under “BIEI” on the OTC-BB Index.
This press release includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Actual results may differ from expectations and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions are intended to identify such forward-looking statements. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results. Additional information concerning these and other risk factors are contained in the Company’s most recent filings with the Securities and Exchange Commission. The Company cautions readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in their expectations or any change in events, conditions or circumstances on which any such statement is based, except as required by law.
About Uptick Newswire and the “Stock Day” Podcast
Founded in 2013, Uptick Newswire is the fastest growing media outlet for Nano-Cap and Micro-Cap companies. It educates investors while simultaneously working with penny stock and OTC companies, providing transparency and clarification of under-valued, under-sold Micro-Cap stocks of the market. Uptick provides companies with customized solutions to their news distribution in both national and international media outlets. Uptick is the sole producer of its “Stock Day” Podcast, which is the number one radio show of its kind in America. The Uptick Network “Stock Day” Podcast is an extension of Uptick Newswire, which recently launched its Video Interview Studio located in Phoenix, Arizona.
Investors Hangout is a proud sponsor of “Stock Day,” and Uptick Newswire encourages listeners to visit the company’s message board at https://investorshangout.com/
SOURCE:
Uptick Newswire
https://upticknewswire.com/
